Avanos Medical to be acquired by AIP for $25/share, $1.272B enterprise value

AVANOS MEDICAL, INC.

Avanos stockholders receive $25.00 per share in cash; enterprise value approx. $1.272B.
Premium of 72.1% to April 13 closing price and 82.8% to 30-day VWAP.
Acquisition unanimously approved by Avanos Board; expected to close H2 2026.
Closing conditions include stockholder approval and HSR clearance; no financing condition.
Avanos common stock will be delisted from NYSE; 2026 annual meeting postponed.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AVANOS MEDICAL, INC. entered into Agreement and Plan of Merger with A-AV Holdco I, Inc. and A-AV MergerSub, Inc. valued at $25.00 per Share in cash (effective 2026-04-13).

Action: entry
Agreement: merger
Counterparty: A-AV Holdco I, Inc. and A-AV MergerSub, Inc.
Value: $25.00 per Share in cash
Effective: 2026-04-13

Exact text from the filing

On April 13, 2026, Avanos Medical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, A-AV Holdco I, Inc., a Delaware corporation (“Parent”), and A-AV MergerSub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Subsidiary”).

View on SEC.gov

Browse all material agreements →

AVANOS MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001606498-26-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.